

# INSPIREMD, INC.

## **FORM 8-K** (Current report filing)

Filed 01/26/18 for the Period Ending 01/26/18

Telephone	(888) 776-6804
CIK	0001433607
Symbol	NSPR
SIC Code	3841 - Surgical and Medical Instruments and Apparatus
Industry	Medical Equipment, Supplies & Distribution
Sector	Healthcare
Fiscal Year	12/31

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

---

Date of Report (Date of earliest event reported): January 26, 2018

**InspireMD, Inc.**

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction  
of incorporation)

001-35731

(Commission  
File Number)

26-2123838

(IRS Employer  
Identification No.)

4 Menorat Hamaor St.  
Tel Aviv, Israel

(Address of principal executive offices)

6744832

(Zip Code)

Registrant's telephone number, including area code: (888) 776-6804

---

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 8.01 Other Events.**

On January 26, 2018, InspireMD, Inc. announced that its CGuard™ Embolic Prevention System will be featured in two separate live case transmissions at the Leipzig Interventional Course (LINC) 2018 to be held from January 30th to February 2nd at the Trade Fair Leipzig, Hall 2 in Leipzig, Germany. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit Number</b>	<b>Description</b>
99.1	<a href="#">Press release dated January 26, 2018</a>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**InspireMD, Inc.**

Date: January 26, 2018

By: /s/ Craig Shore

Name: Craig Shore

Title: Chief Financial Officer

---





**InspireMD's CGuard™ Embolic Prevention System  
to be Prominently Featured in Two Live Case Transmissions at LINC 2018**

Tel Aviv, Israel— January 26, 2018 - InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard™ Embolic Prevention System (EPS) will be featured in two separate live case transmissions at the Leipzig Interventional Course (LINC) 2018 to be held from January 30th to February 2nd at the Trade Fair Leipzig, Hall 2 in Leipzig, Germany. CGuard™ EPS will also be featured in two scientific sessions and a poster presentation at the conference.

On January 30, from 11:50 AM – 12:16 PM Central European Time, Dr. Antonio Micari and Dr. Fausto Castriota, interventional cardiologists with Maria Cecilia Hospital, Cotignola, Italy, will perform a live endovascular procedure entitled, “Symptomatic left internal carotid disease in a 79-year old woman,” featuring CGuard™ EPS that will be transmitted real time to the congress.

On January 30, from 4:30 – 6:00 PM Central European Time, Dr. Andrej Schmidt and Dr. Matthias Ulrich from the Department of Angiology, University Hospital Leipzig, Division of Interventional Angiology, Leipzig, Germany, will perform a live endovascular procedure entitled, “Restenosis after TEA left internal carotid artery,” featuring CGuard™ EPS that will be transmitted real time to the congress.

The CGuard™ Carotid Embolic Prevention System will also be featured at the Company's booth (18c2).

Additional presentations featuring CGuard™ EPS will include:

What: Comparative analysis of new mesh-covered stent designs using MRI parameters (Maria Antonella Ruffino, MD, EBIR; Italy)  
When: January 30, 10:05 – 10:12 AM Central European Time  
Where: Room 3 - Technical Forum

What: Transcervical carotid stenting (TECAR) with flow reversal vs. CEA in highly symptomatic patients (Professor Ralf R. Kolvenbach MD, PhD, FEBVS; Germany)  
When: January 30, 10:26 – 10:33 AM Central European Time  
Where: Room 3 - Technical Forum

CGuard™ EPS will also be featured in a poster presentation, entitled, “Single-center experience with MicroNet covered embolic prevention stent in a treatment of vulnerable carotid plaque: short and mid-term results” (Valdimir Gavrilovic, MD; Italy) on January 31, from 3:00 - 3:05 PM Central European Time in front of the Main Arena 1.

---

LINC is a leading global forum for new methods in the field of vascular medicine. LINC brings together medical professionals from different specialties around the world who perform endovascular interventions.

“It is a true honor to have CGuard™ EPS, once again, chosen by these leading physicians to be prominently featured in two live case transmissions at LINC 2018, in addition to the two podium presentations and a poster presentation,” said James Barry, PhD, Chief Executive Officer of InspireMD. “This continues to support the progress we have made in demonstrating the truly meaningful safety benefits of CGuard™ EPS and this can be seen in the support we are receiving from key opinion leaders in Europe and around the world.”

#### **About InspireMD, Inc.**

InspireMD seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.

InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS.

#### **Investor Contacts:**

InspireMD, Inc.  
Craig Shore  
Chief Financial Officer  
Phone: 1-888-776-6804 FREE  
Email: [craigs@inspiremd.com](mailto:craigs@inspiremd.com)

Crescendo Communications, LLC  
David Waldman  
Phone: (212) 671-1021  
Email: [NSPR@crescendo-ir.com](mailto:NSPR@crescendo-ir.com)

---

